A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib

Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previously received erlotinib. A 42-year-old male who was diagnosed as lung adenocarcinoma and received many series of cytotoxic regimens. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy. After progressive disease, biopsy of new liver lesion showed EML4/ALK rearrangement. Thus crizotinib was administrated. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy and chemotherapy. We conclude that it is important to evaluate for EML4/ALK rearrangement even the patient has EGFR mutation. Concomitant EGFR exon 18 and EML4-ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients. Keywords: Non-small cell lung cancer, Erlotinib, Epidermal growth factor receptor, Anaplastic lymphoma kinase, Crizotini

Synthesis of taurine-Cu-3(PO4)(2) hybrid nanoflower and their peroxidase-mimic and antimicrobial properties

Herein, we report the synthesis of taurine incorporated (sulfur containing organic molecule derived from methionine and cysteine) hybrid nanoflowers (thNFs) with an intrinsic peroxidase-mimic and antimicrobial activities in the presence of H2O2. Formation of thNFs using non-enzyme molecules was for the first time and systematically studied as a function of the taurine concentration, types of metal ions (Cu2+, Fe2+ and Fe3+) and pH values of reaction solution. The peroxidase like activities of thNFs rely on Fenton-like reaction against guaiacol used as a model substrate. The efficiency of Fenton reaction can be attributed to porous structure and presence of ions of transition elements in the thNFs. The thNFs were further characterized using FTIR, XRD, SEM and EDX. The thNFs also showed remarkable antimicrobial properties against S. aureus, E. coli, B. cereus and C. albicans. We claim that nonprotein-based NFs can be considered as new generation nano-biocatalysts as an alternative to enzymes and can be used in various medicinal, biochemical, immunological, biotechnological, and industrial applications.Erciyes University TYL-2018-8578 TCD-2019-848

Survivin Expression May Affect The Neoadjuvantchemotherapy Response İn Breast Cancer Patients

To investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients. Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n52). Event -free survival (EFS) (defined as recurrence or metastasis free) analyze was performed. The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p>0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p0.038, p0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze. Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials